
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma
Details : 123-I ATT001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Details : The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent gl...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $2.5 million
June 01, 2023
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition

Details : 68-Ga THP-PSMA is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
August 06, 2018
